Study On Side Effects Of Oral Propranolol For Infantile Hemangioma In The First Week

Objective: To investigate the necessity of hospitalization by analyzing the severity of side effects in infantile hemangioma patients with oral propranolol in the first week,.Methods: Retrospectively analysis were performed on the clinical data from 502 patients with high-risk infantile hemangioma who hospitalized and treated with oral proranolol in the first week from April 2013 to April 2017.The side effects were summarized.Results: There were 152 males and 350 females among 502 patients with infants hemangiomas treated with oral propranolol.The ratio of females to male was 1: 2.3.The mean age was 3 months(range 1 to 15 months).The location of lesions were 315(62.75%)on head and neck,97(19.32%)on trunk,40(7.97%)on limbs,13(2.59%)on head and neck,3(0.60%)on trunk and extremities,6(1.20%)on head,neck and extremities.26(5.18%)with multiple hemangiomas(?5 lesions),of which 2 patients with liver involvement.7 cases developed ulceration on lip,armpit,chest,neck,perineum,forearm,head respectively.There were 38(7.57%)cases having history of prematurity,17(3.39%)cases having history of low birth weight,47(9.36%)cases having history of heart disease.21(4.18%)casese were detected abnormal liver function and 31(6.18%)cases with high level of blood TSH.The total rate of side effects among 502 patients was 18.52%(93/502),in which 4.58%(23/502)with bradycardia,0.40%(2/502)with ? degree atrioventricular block,but all without clinical manifestations.12.55%(63/502)with gastrointestinal discomfort,0.40%(2/502)with poor appetite,0.20%(1/502)with hypersomnia and 0.40%(2/502)with cold extremities.502 patients with IH were divided into four groups according to age.The adverse events of each group showed 10.71%(3/28)in age less than or equal to 5 weeks,14.22%(31/218)in age between 5 weeks and 3 months,23.9%(49/205)in age between 3months and 6 month,19.61%(10/51)in age greater or equal to 6months.No significant difference was showed between bradycardia gastrointestinal discomfort after taking propranolol and the factors including age,gender,history of premature birth or low birth weight,history of congenital heart disease,elevated TSHbefore treatment and abnormal liver function,respectively(P> 0.05).Conclusion: The therapy of oral propranolol for high-risk infantile hemangiomas is a relatively safe method accompanying minor side effects.Patients excluding special populations and with no obvious contraindications can be monitored in a short period after taking propranolol in outpatient,and the administered dose can be adjusted according to the follow-up visit.The hospitalization is unneeded.